Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Pulmatrix Inc (PULM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.52+14.29%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.58 → 0.58 EPS · FY ending Dec 31, 2027 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for PULM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Operating cash flow improves to at least -$1.07M by 2026-Q1 | Pulmatrix is improving cash flow, cutting losses from -$3.68M to -$1.07M. | Broken | operating cash flow worse than -1.07 million USD by 2026-Q1 | Cash from operations: $-1.106M FY2026-Q2; GAAP. Published target: >= -1.07 million USD. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026-1,106,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, high-risk biotech situation rather than an established earnings compounder. The long-term thesis is in a watch state: management is advancing its merger plans, but recent financial performance is weak and the company is loss-making.
The valuation model describes PULM as cheap versus peers, while the expectations gap is slightly negative, suggesting expectations are not especially forgiving. The priced-in assessment is tagged justified, with low fragility, so the evidence does not point to unusually concentrated market expectations.
Near term, the risk of an earnings miss is elevated, and a guidance cut on the next call would be a meaningful setback. Management has progressed toward the Eos SENOLYTIX merger and raised $1 million through a private placement, but completing the merger and monetizing clinical assets remain open tasks.
The multi-year view hinges on completing the merger as planned and making progress with assets including PUR1900 and PUR3100. Near-term conditions also matter: weakening jobs data could weigh on cyclical and healthcare names, while continued strength from sector bellwethers could support healthcare-sector momentum.
As of 2026-10-24, PULM’s long-term thesis is fragile because losses and weak recent performance outweigh the progress visible in merger preparations. The next call, merger completion, and evidence of asset monetization are key tests. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Cash sufficient to fund operations into 2027-Q1 |
| The company plans to have enough cash to operate into early 2027. |
| Intact |
| cash runway falls short of 2027-Q1 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Complete merger with Eos SENOLYTIX | A supporting condition in Pulmatrix Inc's published investment case. The stated target is merger finalized and integrated. | Improving | merger not completed or integration fails by 2026-Q2 | Merger signed 2026-03-26; target 2026-Q2 Pulmatrix and Eos signed merger agreement on March 26, 2026. No news of completion or failure yet. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.58 → $0.58 · observed estimates
$0.03B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-07-25 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-07-26 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-07-27 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-07-28 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-07-29 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-07-30 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-07-31 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-01 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-02 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-03 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-04 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-05 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-06 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-07 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-08 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-09 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-10 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-12 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-13 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-14 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-15 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-16 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-17 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-18 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-19 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-20 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-21 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-22 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-23 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-24 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-25 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-26 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-27 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-28 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-29 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-30 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-08-31 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-01 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-02 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-03 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-04 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-05 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-06 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-07 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-08 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-09 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-10 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-11 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-12 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-13 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-14 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-15 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-16 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-17 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-18 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-19 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-20 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-21 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-22 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-23 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-24 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-25 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-26 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-27 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-28 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-29 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-09-30 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-01 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-02 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-03 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-04 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-05 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-06 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-07 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-08 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-09 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-10 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-11 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-12 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-13 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-14 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-15 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-16 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-17 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-18 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-19 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-20 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-21 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-22 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-23 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-24 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-25 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-26 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-27 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-28 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-29 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-30 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-10-31 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-11-01 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-11-02 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-11-03 | $0.58 | $27,521,000 | 1 / 1 |
| 2026-11-04 | $0.58 | $27,521,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.